Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants were dosed (https://ibn.fm/JXADp).
“To commence dosing in our first-in-human phase 1/2a trial is a tremendous milestone for Cybin, especially having reached the clinic within just 18 months,” said Cybin CEO Doug Drysdale. “Our goal continues to focus on becoming a leader in creating the best psychedelic therapies for patients, and today we have moved one step closer. Through our rigorous preclinical work and ongoing clinical development of CYB003, we believe we have the potential to unlock the powerful benefits of psilocybin for the treatment of major depressive disorder (‘MDD’) without its well-known limitations.”
The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration of effect, compared to oral psilocybin. CYB003 has the potential to reduce time in the clinic, which could allow more scalability and access for this treatment.
As a randomized, double-blind, placebo-controlled study, the current phase 1/2a trial will evaluate individuals with moderate to severe MDD. Those who qualify for the study are between the ages of 21 and 55, have a verified diagnosis of MDD and are unsatisfied with their current prescribed medication and treatment. Participants will be allowed to remain on their current medication throughout the trial.
“The high level of participant interest in our study serves to validate the significant unmet need for alternative and better treatment options to improve mental health conditions,” said Drysdale. “We expect that this phase 1/2a trial will provide valuable insights and data. These findings will be critical in establishing a safe and efficacious treatment profile for CYB003 so we can continue to progress our mission to help revolutionize the treatment landscape for people suffering from depression.”
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, and novel formulation approaches and treatment regimens for mental health disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About TinyGems
TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.
To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems Los Angeles, California www.TinyGems.com 310.299.1717 Office Editor@TinyGems.com
TinyGems is part of the InvestorBrandNetwork
Frontieras is developing breakthrough technologies that convert abundant solid hydrocarbons such as coal into cleaner…
LIXT is advancing its lead compound LB-100 across different clinical programs aimed at difficult-to-treat cancers…
The National Transportation Safety Board (“NTSB”) has intensified its focus on collision-prevention technologies following multiple…
LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness…
Jack Dorsey is making a concrete bet that artificial intelligence can replace what middle managers have…
Scientists have overcome production barriers that have plagued doxorubicin manufacturing since the 1970s by engineering…